Loading PFE detail
Loading ticker data...
Loading PFE detail
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Chart data unavailable
Pfizer boasts a juicy 6.4% dividend yield. Ongoing clinical progress could help rejuvenate its lineup.
ABBV edges out PFE as Skyrizi and Rinvoq fuel strong growth, offsetting Humira losses and positioning the drugmaker for sustained expansion.
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
BOCHK Asset Management Ltd raised its holdings in shares of Pfizer Inc. (NYSE: PFE) by 2,915.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,200 shares of the biopharmaceutical company's stock after acquiring an additional 37,900 shares during the quarter. BOCHK
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number.
Rexford Industrial Realty and Pfizer are both priced as if their best days are over, but I see long-term value. REXR benefits from supply-constrained Southern California markets, resilient rent growth, disciplined management, and trades at a deep discount to historical valuation. PFE faces a patent cliff but is actively rebuilding its pipeline through targeted acquisitions, maintaining a strong balance sheet and well-covered 6.3% dividend.
Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
Asio Capital LLC purchased a new stake in shares of Pfizer Inc. (NYSE: PFE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 114,830 shares of the biopharmaceutical company's stock, valued at approximately $2,859,000. A number of other institutional
Pfizer (PFE) concluded the recent trading session at $27.1, signifying a -2.62% move from its prior day's close.
He continues to consider Pfizer a sell. The pundit's main concern is the company's weaknesses in three key products.
Pfizer sentiment is also getting tugged by Washington policy risk after a potential 100% tariffs framework surfaced for drugmakers without pricing deals, with an announcement timeline as soon as Thursday.
Pfizer's declining revenue and questions about its growth have weighed down the stock in recent years. The company, however, has been bolstering its pipeline and has some exciting assets.
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories.
Leo Wealth LLC grew its holdings in shares of Pfizer Inc. (NYSE: PFE) by 25.4% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,861 shares of the biopharmaceutical company's stock after acquiring an additional 27,559 shares during the quarter. Leo Wealth LLC's
Stratos Wealth Partners LTD. reduced its holdings in shares of Pfizer Inc. (NYSE: PFE) by 14.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,361 shares of the biopharmaceutical company's stock after selling 35,463 shares during the quarter. Stratos
